Pralay Mukhopadhyay PhD

Dr. Mukhopadhyay is an experienced statistician with a proven track record in oncology drug development. He currently works as the head of statistics for late-stage immuno-oncology (IO) group in AstraZeneca (AZ). During this period, he has made significant contributions in the development of Durvalumab, an anti-PDL1 agent, in Urothelial and Lung Cancer. Prior to joining AZ, he was at Bristol Myers Squibb, where he was involved in their late-stage oncology development program. During this time, he was instrumental in the development of several anti-cancer agents in both solid tumors and hematologic malignancies.

Dr. Mukhopadhyay has represented his organization in advisory committee meetings with health authorities (HA) across the globe. He has participated in discussions with FDA, Health Canada and ANVISA (Brazilian HA) in broader development challenges of IO agents. He has been an invited speaker at the EMA’s workshop on immunotherapy, ISPOR annual meetings, Duke-Industry Statistics Workshop, Society for Clinical Trials and at the International Society for Biopharmaceutical Statistics (ISBS). He is also a core member of the FDA-industry cross-PhRMA working group evaluating statistical challenges in the design and analysis of IO trials. He has published in peer reviewed journals and has served as a referee in reputed statistical journals. He received his PhD in statistics from North Carolina State University.